Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 12006 Views
-
Last post by NHE
-
- 0 Replies
- 1174 Views
-
Last post by NHE
-
- 0 Replies
- 1945 Views
-
Last post by frodo
-
- 0 Replies
- 1246 Views
-
Last post by frodo
-
- 0 Replies
- 2110 Views
-
Last post by NHE
-
- 0 Replies
- 1698 Views
-
Last post by frodo
-
- 0 Replies
- 1312 Views
-
Last post by NHE
-
- 1 Replies
- 1793 Views
-
Last post by frodo
-
- 0 Replies
- 2527 Views
-
Last post by NHE